05



(c)

Enrolment No. \_\_\_\_ Seat No.: \_\_\_\_

## GUJARAT TECHNOLOGICAL UNIVERSITY

B.Ph. - SEMESTER-VII • EXAMINATION - WINTER-2018 Subject Code: 2270015 Date: 28/11/2018 **Subject Name:** Quality by Design (QbD) and Process Analytical Technology (PAT) Time: 10:30AM TO 01:30PM **Total Marks: 80 Instructions:** 1. Attempt any five questions. 2. Make suitable assumptions wherever necessary. 3. Figures to the right indicate full marks. **Q.1** Discuss the Process performance and product quality monitoring system as an 06 (a) element of ICH Q10 Pharmaceutical Quality System. Draw the CTD triangle and Explain the Module 5 Clinical study reports. 05 **(b)** Write a note on HACCP (Hazard Analysis and Critical Control Points). (c) 05 Define ObD. Discuss the elements of ObD. **Q.2** (a) 06 Write two primary principles of QRM and Draw the flow chart of typical **(b)** 05 Quality Risk Management Process. Write a note on PAT tools. 05 (c) Explain the Ishikawa Diagram that used as a Risk Assessment Tool. **Q.3** (a) 06 Define PAT. Discuss scope and principle of PAT. **(b)** 05 Explain Yate's method for optimization with example. 05 (c) Explain the terminology QTPP and CPP with suitable example with respect to **Q.4** 06 (a) QbD. What is Risk Priority Number? Explain with any Risk Assessment Example. 05 **(b)** Write the total number of experiments and treatment combination and 05 (c) interaction chart for 3<sup>2</sup> Factorial design. Compare the Traditional and QbD approach for Pharmaceutical product supply. 0.5 (a) 06 Explain with example 1) COA 2) CMA **(b)** 05 Write about need of QbD for Pharma sector. 05 (c) **O.** 6 (a) Discuss challenges for implementation of QbD. **06** Explain the Real Time Release Study of PAT. **(b)** 05 Explain the mapping of CMA and CPP to CQAs with example. (c) 05 Explain the CTD module 3 Quality in detail. **Q.7** 06 (a) **(b)** Explain the Design Space. 05

\*\*\*\*\*\*\*\*\*

Explain the control strategy approach for Quality product.